生物发明公司的新癌症药物BI-1910在早期试验中显示了希望,证明是有效和安全的。 BioInvent's new cancer drug BI-1910 shows promise in early trials, proving effective and safe.

国际生物发明组织宣布,其第一阶段BI-1910研究取得了积极成果,这是对固态肿瘤的新治疗。 BioInvent International has announced positive results from its Phase 1 study of BI-1910, a new treatment for solid tumors. 该药物在单独使用时显示出希望,其有效性和安全性方面的数据令人鼓舞。 The drug showed promise when used alone, with encouraging data on its effectiveness and safety profile. 这一早期试验是今后可能为癌症患者进行的临床应用的一个步骤。 This early-stage trial is a step towards potential future clinical applications for cancer patients.